Abstract
Flavonoids are one of the most abundant secondary metabolites having a polyphenolic structure in plant and animal species with various desired pharmacological effects towards human health. Many flavonoid derivatives have been reported to possess neuroprotective activity through different mechanisms of action and, among them, cholinesterase (ChE) inhibition constitutes an important clinically applied treatment strategy of Alzheimer’s disease (AD). Some flavonoid derivatives have been demonstrated to inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to varying extent, which are called the sister enzymes linked to the pathogenesis of AD. On the other hand, diverse bioproduction techniques such as plant tissue culture, microbial transformation, etc. are applicable for flavonoids and, among them, production of flavonoids through metabolic engineering using special bacteria or yeast species has recently become popular. In the current review, some common flavonoids with ChE inhibitory effect as well as the examples of flavonoids obtained from metabolic engineering methods will be discussed.
Keywords: Alzheimer's disease, bioproduction, cholinesterase inhibition, flavonoid, metabolic engineering.
Current Pharmaceutical Biotechnology
Title:Implications of Some Selected Flavonoids Towards Alzheimer’s Disease with the Emphasis on Cholinesterase Inhibition and their Bioproduction by Metabolic Engineering
Volume: 15 Issue: 4
Author(s): Ilkay E. Orhan
Affiliation:
Keywords: Alzheimer's disease, bioproduction, cholinesterase inhibition, flavonoid, metabolic engineering.
Abstract: Flavonoids are one of the most abundant secondary metabolites having a polyphenolic structure in plant and animal species with various desired pharmacological effects towards human health. Many flavonoid derivatives have been reported to possess neuroprotective activity through different mechanisms of action and, among them, cholinesterase (ChE) inhibition constitutes an important clinically applied treatment strategy of Alzheimer’s disease (AD). Some flavonoid derivatives have been demonstrated to inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) to varying extent, which are called the sister enzymes linked to the pathogenesis of AD. On the other hand, diverse bioproduction techniques such as plant tissue culture, microbial transformation, etc. are applicable for flavonoids and, among them, production of flavonoids through metabolic engineering using special bacteria or yeast species has recently become popular. In the current review, some common flavonoids with ChE inhibitory effect as well as the examples of flavonoids obtained from metabolic engineering methods will be discussed.
Export Options
About this article
Cite this article as:
Orhan E. Ilkay, Implications of Some Selected Flavonoids Towards Alzheimer’s Disease with the Emphasis on Cholinesterase Inhibition and their Bioproduction by Metabolic Engineering, Current Pharmaceutical Biotechnology 2014; 15 (4) . https://dx.doi.org/10.2174/1389201015666140813123204
DOI https://dx.doi.org/10.2174/1389201015666140813123204 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Data Integration in Functional Analysis of MicroRNAs
Current Bioinformatics Rho Kinase and Angiogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Is Effective and Safe a Radiochemotherapy Approach in Elderly Cancer Patients? A Review
Anti-Cancer Agents in Medicinal Chemistry Synthesis and In Vitro Biological Evaluation of Novel Pyrazole Derivatives as Potential Antitumor Agents
Medicinal Chemistry The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant
Current Drug Therapy Synthesis of Compounds as Melatonin Agonists and Antagonists
Mini-Reviews in Medicinal Chemistry Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Protein Kinases and their Modulation in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents Novel Treatments of Schizophrenia: Targeting the Neurotensin System
CNS & Neurological Disorders - Drug Targets Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Current Cancer Therapy Reviews Oncologic Imaging End-Points for the Assessment of Therapy Response
Recent Patents on Anti-Cancer Drug Discovery State of the Art of Biochemical Markers in Metastatic Bone Disease and the Role of Bisphosphonates as Therapeutic Agents
Current Pharmaceutical Analysis Role of Nuclear Imaging in Cardiac Amyloidosis Management: Clinical Evidence and Review of Literature
Current Medical Imaging